The forgotten class of drugs for multiple myeloma: HDAC inhibitors

被引：6

作者：

Biran, Noa

Siegel, David S. ^{[1
]}

Vesole, David H.

机构：

[1] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ 07601 USA

来源：

LANCET HAEMATOLOGY | 2018年 / 5卷 / 12期

关键词：

BORTEZOMIB; DEXAMETHASONE; COMBINATION; LENALIDOMIDE; VORINOSTAT;

D O I：

10.1016/S2352-3026(18)30194-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E604 / E605

页数：2

共 10 条

[1]

Andrzej J, 2017, P AM SOC CLIN ONCO S, V35, P8000

[2] Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study [J].

Dimopoulos, Meletios ;

Siegel, David S. ;

Lonial, Sagar ;

Qi, Junyuan ;

Hajek, Roman ;

Facon, Thierry ;

Rosinol, Laura ;

Williams, Catherine ;

Blacklock, Hilary ;

Goldschmidt, Hartmut ;

Hungria, Vania ;

Spencer, Andrew ;

Palumbo, Antonio ;

Graef, Thorsten ;

Eid, Joseph E. ;

Houp, Jennifer ;

Sun, Linda ;

Vuocolo, Scott ;

Anderson, Kenneth C. .

LANCET ONCOLOGY, 2013, 14 (11) :1129-1140

[3] Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial [J].

Durie, Brian G. M. ;

Hoering, Antje ;

Abidi, Muneer H. ;

Rajkumar, S. Vincent ;

Epstein, Joshua ;

Kahanic, Stephen P. ;

Thakuri, Mohan ;

Reu, Frederic ;

Reynolds, Christopher M. ;

Sexton, Rachael ;

Orlowski, Robert Z. ;

Barlogie, Bart ;

Dispenzieri, Angela .

LANCET, 2017, 389 (10068) :519-527

[4] A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma [J].

Jakubowiak, Andrzej J. ;

Dytfeld, Dominik ;

Griffith, Kent A. ;

Lebovic, Daniel ;

Vesole, David H. ;

Jagannath, Sundar ;

Al-Zoubi, Ammar ;

Anderson, Tara ;

Nordgren, Brian ;

Detweiler-Short, Kristen ;

Stockerl-Goldstein, Keith ;

Ahmed, Asra ;

Jobkar, Terri ;

Durecki, Diane E. ;

McDonnell, Kathryn ;

Mietzel, Melissa ;

Couriel, Daniel ;

Kaminski, Mark ;

Vij, Ravi .

BLOOD, 2012, 120 (09) :1801-1809

[5]

Kaufman JL, 2012, ASH ANN M, V120, P336

[6] Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial [J].

Manasanch, Elisabet E. ;

Shah, Jatin J. ;

Lee, Hans C. ;

Weber, Donna M. ;

Thomas, Sheeba K. ;

Amini, Behrang ;

Feng, Lei ;

Berkova, Zuzana ;

Hildebrandt, Michelle ;

Orlowski, Robert Z. .

LANCET HAEMATOLOGY, 2018, 5 (12) :E628-E640

[7] Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma [J].

Mateos, M. -V. ;

Dimopoulos, M. A. ;

Cavo, M. ;

Suzuki, K. ;

Jakubowiak, A. ;

Knop, S. ;

Doyen, C. ;

Lucio, P. ;

Nagy, Z. ;

Kaplan, P. ;

Pour, L. ;

Cook, M. ;

Grosicki, S. ;

Crepaldi, A. ;

Liberati, A. M. ;

Campbell, P. ;

Shelekhova, T. ;

Yoon, S. -S. ;

Iosava, G. ;

Fujisaki, T. ;

Garg, M. ;

Chiu, C. ;

Wang, J. ;

Carson, R. ;

Crist, W. ;

Deraedt, W. ;

Nguyen, H. ;

Qi, M. ;

San-Miguel, J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (06) :518-528

[8] Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications [J].

Mitsiades, CS ;

Mitsiades, NS ;

McMullan, CJ ;

Poulaki, V ;

Shringarpure, R ;

Hideshima, T ;

Akiyama, M ;

Chauhan, D ;

Munshi, N ;

Gu, XS ;

Bailey, C ;

Joseph, M ;

Libermann, TA ;

Richon, VM ;

Marks, PA ;

Anderson, KC .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (02) :540-545

[9] A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens [J].

Sanchez, Larysa ;

Vesole, David H. ;

Richter, Joshua R. ;

Biran, Noa ;

Bilotti, Elizabeth ;

McBride, Laura ;

Anand, Palka ;

Ivanovski, Kristin ;

Siegel, David S. .

BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (03) :440-447

[10] Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma [J].

Vogl, Dan T. ;

Raje, Noopur ;

Jagannath, Sundar ;

Richardson, Paul ;

Hari, Parameswaran ;

Orlowski, Robert ;

Supko, Jeffrey G. ;

Tamang, David ;

Yang, Min ;

Jones, Simon S. ;

Wheeler, Catherine ;

Markelewicz, Robert J. ;

Lonial, Sagar .

CLINICAL CANCER RESEARCH, 2017, 23 (13) :3307-3315

← 1 →